Source link : https://www.newshealth.biz/health-news/radioligand-gets-big-win-in-high-grade-gep-neuroendocrine-tumors/
SAN FRANCISCO — Adding a radioligand to standard therapy almost tripled median progression-free survival (PFS) in untreated high-grade gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a randomized trial showed. Median PFS increased from 8.5 months with high-dose octreotide to 22.8 months with 177Lu-Dotatate (Lutathera) plus standard-dose octreotide. The objective response rate improved from 9.3% to 43.0%, and benefits […]
Author : News Health
Publish date : 2024-01-20 15:11:22
Copyright for syndicated content belongs to the linked Source.